Amylin’s Bydureon Approval: How Does It Sit With Novo Nordisk?
• By Wendy Diller
Sponsor of the leading GLP-1 agonist, Victoza, sees the launch of the long-acting competitor from Amylin as having a class-wide impact, drawing more patients to GLP-1s – and it thinks that it can stave off the once-weekly contender.
Competitors see the U.S. approval of Amylin Pharmaceuticals Inc.’s type 2 diabetes drug Bydureon (long-acting exenatide) on Jan. 27 as an event that will boost interest in the entire GLP-1 class, benefiting other agents as well.
Novo Nordisk AS has come out swinging in the wake of Amylin’s long-time-coming success, and it will be interesting...